Gene Delivery
Gene Delivery (aka Gene Therapy) offers the ability to permanently correct a disease at its most basic level, the genome, and offers cures for many conditions that are considered incurable at this time, including biological aging.
​
Our in Vivo Gene Delivery procedure is administered as follows:
- A section of the DNA/gene containing instructions for making the useful protein (Telomerase) is packaged within an AAV* viral vector.
- The viral vector is then injected, acting as a vehicle to carry the new DNA into the cells of the patient.
- Once inside the cells of the patient, the gene is expressed by the cell’s normal machinery leading to production of the therapeutic protein.
​
​
​
​
​
​
​
​
*AAV (Adeno-Associated Virus) vectors are not pathogenic to humans and cause limited and infrequent immune responses. Our AAV vector targets both dividing and non-diving cells and persists in an extrachromosomal state without integrating into the genome of the host cells.
​
Key AAV vectors advantages:
- Minimal immunogenicity/infectivity
- Non pathogenic to humans
- Low immune response
- Long-term Gene Expression
- Multiple Serotypes
- Efficient Transduction
- Dividing/Non-Dividing Cells
Activated Human Telomerase Gene
AAV Vector
Hybrid Virus
Gene Delivery explained
Our patented Gene Delivery Therapy is available only in Selected Regional clinics: please contact us for more information.
​
To prove the efficacy and safety of our Gene Delivery treatments we are conducting a Human Clinical Trial targeting Alzheimer's in cooperation with our sister company Libella Gene Therapeutics: more information can be found at the below link.